

Biologics & Biosimilars: Impact of Amgen and Hot Topics in Biosimilar Litigation

EARN 1.5 AREAS OF PROFESSIONAL PRACTICE NY/NJ CLE CREDIT FOR BOTH NEWLY ADMITTED & EXPERIENCED ATTORNEYS

Wednesday, February 7, 2024 Kramer Levin Naftalis & Frankel LLP

Mark with an X the appropriate boxes in rating the following aspects of the program facilities.

	Excellent	Good	Fair	Poor
Facility				
Technology				
Registration				
Refreshment				
Overall Program				

Mark with an X the appropriate boxes in rating the following aspects of the program.

		Excellent	Good	Fair	Poor
	Written Materials				
Larry Coury, Regeneron	Quality of Presentation				
Mira Mulvaney, Eli Lilly and Company	Quality of Presentation				
Jen Reda, Johnson & Johnson	Quality of Presentation				
Irena Royzman, Kramer Levin Naftalis & Frankel LLP	Quality of Presentation				

reas for improvement and additional comments.							
What segments of the program were of most value to you?							
2. What segments of the program were of least value to you?							
•							
. How did you first learn about	:his program?						
NYIPLA Website	E-mail	Social Media	Word of Mouth				
Other:							
ttorney Name (Print Clearly)		Attorney Signature					

Thank you for participating!
PLEASE HAND IN COMPLETED EVALUATION FORM OR EMAIL TO ADMIN@NYIPLA.ORG.

Materials are available online at:

https://www.nyipla.org/assnfe/ev.asp?ID=1509